The WHO names Tuberculosis (TB) as one of the top 10 causes of death worldwide and over 95 percent of those deaths occur in low- and middle-income countries. To improve the global health community’s understanding of TB and provide information that could help treat it, Notre Dame researchers have developed a new strain of the bacteria along with a new method to better study this deadly disease.
The Office of Technology Transfer (OTT) is now accepting nominations for the 1st Source Bank Technology Commercialization competition. The winner will be revealed at the seventh annual commercialization event on April 18, 2017, and will receive a $20,000 cash award.
Diabetes is a metabolic disease in which the body has an inability to produce enough insulin. In the United States alone, it is estimated that the illness affects nearly 30 million diagnosed and undiagnosed people, and treatment often includes patients using an intravenous or IV method to get insulin into their system. This uncomfortable and inconvenient form of treatment can require anywhere from two to four injections a day, but a Notre Dame researcher is working to combat this problem with a less frequent, oral delivery system.
Each year, SPARK, a Stanford University initiative that provides the education and mentorship in order to advance research discoveries from the bench to the bedside, hosts a diverse group to participate in a 12-day training course in biotech innovation and entrepreneurship. The program provides an understanding of how biotechnology products, such as medical devices, food science, and general medical science, and companies are created, established, managed, advertised, and funded. Ricardo Romero, graduate student of the Integrated Biomedical Sciences program and researcher in the Harper Cancer Research Institute, had the opportunity to attend the program through the Indiana Clinical and Translational Sciences Institute (Indiana CTSI).
At the University of Notre Dame, the Molecular Structure Facility (MSF) analyzes organic or inorganic substances at an atomic level, which allows researchers to learn about the three-dimensional structure and connectivity of the compound they have created. Knowing the molecular make-up of substances oftentimes provides faculty, postdoctoral fellows, and graduate students information about whether or not their substance is actually what was intended or even to see if their research is heading in the right direction.
As Richard Taylor completes a three-year term as associate vice president for research in June of this year, he will continue his research on drug discovery for rare genetic diseases, like NGLY1 deficiency, when he and other members of the Warren Family Research Center for Drug Discovery and Development move into the building this summer.
The Indiana Clinical and Translational Sciences Institute (CTSI) has provided support for Olaf Wiest, University of Notre Dame professor of chemistry and biochemistry, and Robert Stahelin, Indiana University School of Medicine associate professor of biochemistry and molecular biology and adjunct associate professor of chemistry and biochemistry at Notre Dame, through the Notre Dame-CTSI Project Development Team.